As people around the world are engulfed in the obesity epidemic chronic disease , we can not reduce our thoughts away from the deadly influence of smoking. And if traits of obesity and smoking go hand in hand very little that can be done for the treatment of such an individual . There have been a number of diet pills that flower markets in recent years, but now for the first time a diet pill to be launched which is to have an additional function as a non- tobacco drug loss weight .
An experimental pill that offers the promise of fairy tale to help people lose weight and stop smoking has already created a stir in the world with much of its population struggle against both vices. The diet pill has been the brain - child of French pharmaceutical group Sanofi -Aventis and will be marketed under the brand name Acomplia . The main component of the diet pill Acomplia is rimonabant . It works by blocking the CB1 receptor , one of two receptors found in a newly described physiological system called the endocannabinoid system ( EC system) seems to play a crucial role in the regulation of food intake and energy expenditure . These receptors are present not only in the region of the hypothalamus of the brain, but also throughout the body , particularly in fat cells - which are involved in lipid and glucose metabolism . They work by reducing dependence on tobacco, suppressing appetite and restore balance in the system. Since many smokers have a tendency to obesity, Acomplia diet drug could serve both needs .
Some analysts have also started considering Acomplia Rimonabant as a heart medication . Implications drugs on the main factors of cardiovascular risk - smoking and obesity can be considered a major medical advance for patients at risk for heart disease. This is the first anti- smoking pill regime to block the CB1 receptors in the brain commonly known as the " pleasure center " of the brain and interfering with the cycle of desire and satisfaction making hunger or cigarette pain more manageable .
Tendency to gain weight quickly was seen in people once they stop taking the weight loss drugs . This is why clinical trials of the drug Rimonabant has been ongoing since 2002 and are still in progress to ensure that the guarantee of trust and submit to its users, because only studies more long term can determine whether the preliminary results of Acomplia trials will result in lasting weight loss . People prone to obesity and smoking have been waiting for the first weight loss drug tobacco to arrive on the market and their fanatic research reports online Acomplia is sufficient evidence of the inherent faith in the pill diet testified people worldwide .
An experimental pill that offers the promise of fairy tale to help people lose weight and stop smoking has already created a stir in the world with much of its population struggle against both vices. The diet pill has been the brain - child of French pharmaceutical group Sanofi -Aventis and will be marketed under the brand name Acomplia . The main component of the diet pill Acomplia is rimonabant . It works by blocking the CB1 receptor , one of two receptors found in a newly described physiological system called the endocannabinoid system ( EC system) seems to play a crucial role in the regulation of food intake and energy expenditure . These receptors are present not only in the region of the hypothalamus of the brain, but also throughout the body , particularly in fat cells - which are involved in lipid and glucose metabolism . They work by reducing dependence on tobacco, suppressing appetite and restore balance in the system. Since many smokers have a tendency to obesity, Acomplia diet drug could serve both needs .
Some analysts have also started considering Acomplia Rimonabant as a heart medication . Implications drugs on the main factors of cardiovascular risk - smoking and obesity can be considered a major medical advance for patients at risk for heart disease. This is the first anti- smoking pill regime to block the CB1 receptors in the brain commonly known as the " pleasure center " of the brain and interfering with the cycle of desire and satisfaction making hunger or cigarette pain more manageable .
Tendency to gain weight quickly was seen in people once they stop taking the weight loss drugs . This is why clinical trials of the drug Rimonabant has been ongoing since 2002 and are still in progress to ensure that the guarantee of trust and submit to its users, because only studies more long term can determine whether the preliminary results of Acomplia trials will result in lasting weight loss . People prone to obesity and smoking have been waiting for the first weight loss drug tobacco to arrive on the market and their fanatic research reports online Acomplia is sufficient evidence of the inherent faith in the pill diet testified people worldwide .
No comments:
Post a Comment